Where does Beam Therapeutics's cash flow data come from?

Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Beam Therapeutics BEAM Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	-$414.64M-4.0%	-$398.58M-3.2%	-$386.4M-2.6%
Depreciation and amortization	$22.37M+0.3%	$22.29M+1.0%	$22.07M+0.4%	$21.98M-0.2%	$22.02M+0.4%
Stock-based compensation	$86.61M-8.1%	$94.24M-9.4%	$104.01M-6.1%	$110.83M-6.1%	$118.06M-2.2%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	-$51.87M+10.1%
Change in other assets	$27.4M+707%	-$4.51M-234%	$3.36M+3.7%	$3.24M+1,495%	-$232K-104%
Change in other liabilities	-$107K+67.6%	-$330K-52.1%	-$217K—	——	——
Change in deferred revenue	-$134.3M+0.8%	-$135.42M-408%	-$26.66M+22.2%	-$34.27M+7.6%	-$37.08M-1.5%
Net gains (losses) on investments	——	——	$6.18M+854%	-$820K+93.6%	-$12.82M+9.0%
Non-cash operating lease expense	——	——	——	——	——
Change in operating lease liabilities	-$13.7M-1.5%	-$13.51M-1.7%	-$13.28M+0.4%	-$13.33M-1.5%	-$13.14M-1.5%
Debt issuance costs and discount amortization	——	——	——	——	——
Change in fair value of contingent consideration	——	——	-$945K-1,252%	$82K+105%	-$1.73M-6.5%
Net cash from operating activities	-$369.73M-7.1%	-$345.1M-2.0%	-$338.18M+1.9%	-$344.82M+1.9%	-$351.38M-1.2%
Capital expenditures	$14.11M-5.6%	$14.95M+5.4%	$14.18M+32.0%	$10.75M+12.3%	$9.57M+7.0%
Purchases of investments	$1.02B-15.3%	$1.21B+42.5%	$848.75M+2.3%	$829.84M+31.6%	$630.37M+29.6%
Proceeds from maturities/sales of investments	——	——	——	$15.67M-78.5%	$72.93M—
Proceeds from sales of equity securities	——	$255.15M+33.3%	$191.36M+50.0%	$127.57M+100%	$63.79M—
Net cash from investing activities	——	——	——	-$144.52M-227%	$113.38M-38.7%
Proceeds from issuance of debt	——	——	——	——	——
Proceeds from issuance of common stock	$6.08M+27.4%	$4.77M-24.6%	$6.33M+2.8%	$6.16M+32.6%	$4.64M-17.1%
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	$101.28M-78.8%	$478.05M-0.3%	$479.61M+0.1%	$479.19M+0.2%	$478.22M+6,082%
Net increase (decrease) in cash	-$239.53M-2,181%	$11.51M—	——	——	——
Interest paid	——	$0—	$0-100%	$10K-44.4%	$18K-43.8%
Amortization Of Debt Discount Premium	——	——	——	——	——
Contingent consideration fair value adjustments	——	——	-$945K-1,252%	$82K+105%	-$1.73M-6.5%
Change In Operating Lease Right Of Use Assets	$10.27M-1.1%	$10.39M+0.4%	$10.35M+1.3%	$10.21M+2.6%	$9.96M+3.0%
Derivative Gain Loss On Derivative Net	$940K-42.7%	$1.64M+3.1%	$1.59M-61.7%	$4.15M-51.2%	$8.5M+254%
Equity Method Investment, Realized Gain (Loss) on Disposal	——	$255.15M+33.3%	$191.36M+50.0%	$127.57M+100%	$63.79M—
Equity Securities, FV-NI, Gain (Loss)	——	——	$6.18M+854%	-$820K+93.6%	-$12.82M+9.0%
Accrued expenses and other liabilities	——	——	——	——	-$51.87M+10.1%
Operating lease liabilities	-$13.7M-1.5%	-$13.51M-1.7%	-$13.28M+0.4%	-$13.33M-1.5%	-$13.14M-1.5%
Other long-term liabilities	-$107K+67.6%	-$330K-52.1%	-$217K—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$27.4M+707%	-$4.51M-234%	$3.36M+3.7%	$3.24M+1,495%	-$232K-104%
Investment Income Net Amortization Of Discount And Premium	$14.87M-6.8%	$15.96M-8.0%	$17.34M-7.4%	$18.73M-6.5%	$20.04M-12.0%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$806.64M-4.3%	$842.49M+11.8%	$753.71M+8.3%	$696.06M-7.6%	$753.32M+10.7%
Sales of and distributions from equity method investments	——	$255.15M+33.3%	$191.36M+50.0%	$127.57M+100%	$63.79M—
Payments Of Debt Issuance Costs	——	——	——	——	——
Common stock issuance for private placement	——	$0—	$0—	$0—	$0—
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	$2M+121%
Equity Issuance Costs In Accounts Payable And Accrued Expenses	——	——	——	——	——
Increase Decrease In Contract With Customer Liability	-$134.3M+0.8%	-$135.42M-408%	-$26.66M+22.2%	-$34.27M+7.6%	-$37.08M-1.5%
Increase Decrease In Operating Lease Liability	-$13.7M-1.5%	-$13.51M-1.7%	-$13.28M+0.4%	-$13.33M-1.5%	-$13.14M-1.5%
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1	——	$7.72M+33.3%	$5.79M—	——	——
Free cash flow	-$383.84M-6.6%	-$360.05M-2.2%	-$352.36M+0.9%	-$355.57M+1.5%	-$360.96M-1.3%
Free cash flow	-$383.84M-6.6%	-$360.05M-2.2%	-$352.36M+0.9%	-$355.57M+1.5%	-$360.96M-1.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Beam Therapeutics's cash flow data come from?: Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.